A detailed history of Cubist Systematic Strategies, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 13,361 shares of SUPN stock, worth $500,903. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,361
Previous 79,632 83.22%
Holding current value
$500,903
Previous $2.13 Million 80.47%
% of portfolio
0.0%
Previous 0.01%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$25.77 - $35.16 $1.71 Million - $2.33 Million
-66,271 Reduced 83.22%
13,361 $416,000
Q2 2024

Aug 14, 2024

BUY
$25.99 - $33.85 $1.03 Million - $1.34 Million
39,479 Added 98.32%
79,632 $2.13 Million
Q1 2024

May 15, 2024

SELL
$27.11 - $35.17 $37,493 - $48,640
-1,383 Reduced 3.33%
40,153 $1.37 Million
Q4 2023

Feb 14, 2024

BUY
$22.72 - $29.68 $943,697 - $1.23 Million
41,536 New
41,536 $1.2 Million
Q1 2023

May 15, 2023

BUY
$34.93 - $42.03 $2.22 Million - $2.67 Million
63,569 Added 789.28%
71,623 $2.59 Million
Q4 2022

Feb 14, 2023

SELL
$31.09 - $37.88 $705,152 - $859,156
-22,681 Reduced 73.8%
8,054 $287,000
Q3 2022

Nov 14, 2022

BUY
$28.79 - $35.41 $884,860 - $1.09 Million
30,735 New
30,735 $1.04 Million
Q2 2022

Aug 15, 2022

SELL
$25.33 - $34.25 $447,505 - $605,094
-17,667 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$28.51 - $32.9 $1.64 Million - $1.9 Million
-57,636 Reduced 76.54%
17,667 $571,000
Q4 2021

Feb 14, 2022

BUY
$26.37 - $34.22 $1.99 Million - $2.58 Million
75,303 New
75,303 $2.2 Million
Q3 2021

Nov 15, 2021

SELL
$23.54 - $31.39 $181,069 - $241,451
-7,692 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$26.72 - $33.19 $205,530 - $255,297
7,692 New
7,692 $237,000
Q1 2021

May 17, 2021

SELL
$24.15 - $31.45 $1.14 Million - $1.49 Million
-47,280 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$17.7 - $25.81 $836,856 - $1.22 Million
47,280 New
47,280 $1.19 Million
Q3 2020

Nov 16, 2020

SELL
$20.2 - $25.05 $1.25 Million - $1.56 Million
-62,091 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$17.09 - $24.89 $595,740 - $867,640
34,859 Added 128.01%
62,091 $1.48 Million
Q1 2020

May 15, 2020

BUY
$14.45 - $24.69 $25,301 - $43,232
1,751 Added 6.87%
27,232 $490,000
Q4 2019

Feb 14, 2020

BUY
$19.93 - $29.13 $267,101 - $390,400
13,402 Added 110.95%
25,481 $604,000
Q3 2019

Nov 14, 2019

SELL
$25.47 - $33.37 $574,221 - $752,326
-22,545 Reduced 65.11%
12,079 $332,000
Q2 2019

Aug 14, 2019

BUY
$29.96 - $38.87 $177,513 - $230,304
5,925 Added 20.65%
34,624 $1.15 Million
Q1 2019

May 15, 2019

BUY
$32.77 - $41.99 $323,833 - $414,945
9,882 Added 52.52%
28,699 $1.01 Million
Q4 2018

Feb 14, 2019

BUY
$30.84 - $49.51 $283,573 - $455,244
9,195 Added 95.56%
18,817 $625,000
Q3 2018

Nov 14, 2018

BUY
$42.7 - $56.55 $265,679 - $351,854
6,222 Added 183.0%
9,622 $484,000
Q2 2018

Aug 14, 2018

BUY
$44.1 - $59.85 $149,940 - $203,490
3,400 New
3,400 $203,000
Q1 2018

May 15, 2018

SELL
$37.15 - $46.9 $273,275 - $344,996
-7,356 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$36.4 - $42.6 $267,758 - $313,365
7,356
7,356 $293,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $2.01B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.